|Title||PharmAbcine, AACR Annual Meeting 2020|
PharmAbcine to Present Preclinical Data on PMC-402, Blood Vessel Stabilization in Tumor Microenvironment at AACR Annual Meeting 2020.
PharmAbcine Inc. (KOSDAQ: 208340) announced today that it will present a poster on PMC-402 at the American Association for Cancer Research (AACR) Annual Meeting 2020 that will be held on Apr. 24th – Apr. 29th in San Diego, CA. The poster will be presented in the “Angiogenesis and vascular normalization in tumor immunity and treatment response” session.
PMC-402 is a next generation therapeutic antibody that regulates the formation of functional blood vessels. During the presentation, PharmAbcine will highlight a unique molecular mechanism of PMC-402 and its anti-tumor activity, supported by preclinical data including changes in capillary formation, improvement of hypoxic condition in TME, and increased numbers of TILs (Tumor Infiltrating Lymphocytes) upon a treatment with PMC-402. PharmAbcine will also present PMC-402’s anti-tumor effect observed in a colon cancer model following a single agent therapy or combination therapy with anti-PD1 antibody. The details of poster presentation are as follows:
- Ÿ Title: A novel anti-Tie2 antibody stabilized vessel and increased tumor infiltrated lymphocyte
- Ÿ Session Title: Angiogenesis and Vascular Normalization in Tumor Immunity and Treatment Response
- Ÿ Session Date and Time: Monday Apr 27, 2020, 9:00 AM- 12:30 PM (PST)
- Ÿ Location: San Diego Convention Center, Exhibit Halls A-F, Poster Section 14
- Ÿ Poster Board Number: 10
- Ÿ Permanent Abstract Number: 1483
PharmAbcine has been developing PMC-402 by utilizing years of experience and expertise in developing therapeutic antibodies, including an anti-VEGFR2 antibody, olinvacimab, which is currently in a phase II clinical trial. On the grounds that PMC-402 can constitutively induce normalization of leaky blood vessels formed around tumor mass in a ligand-independent manner, PMC-402 demonstrated its anti-tumor effect in a mouse model of colon cancer, corroborated by the improvement in immune cell infiltration and delivery of anti-cancer agents to a tumor site when administered as a single agent or as a combination therapy regimen. In addition to treating cancer patients, attributed to its notable activity in restoring pathological leaky blood vessels, we expect that PMC-402 will be beneficial to treat AMD or DR patients. PharmAbcine is planning to initiate IND enabling studies this year and submit IND in 2021.
About PharmAbcine Inc.
PharmAbcine is a clinical-stage biotech company focusing on the development of fully human antibody (mAb) therapeutics, especially reputed for leading the development of next-generation multi-specific antibodies. This multi-specific antibody technology can be achieved through our in-house novel technology development, namely DIG-Body, PIG-Body and TIG-Body. Using innovative discovery technology and excellent human resources, we provide a number of superlative immunotherapeutics for indications in immuno oncology, immunology and ophthalmology.
PharmAbcine’s HuPhage library and innovative selection system are priceless proprietary assets. Additionally, our well-established 3G expression system ultimately helped concrete our stupendous reputation in the field of biopharma industry by allowing us to achieve the reinforcement and reproducibility of high levels of antibody production. On the basis of its highly maintained, advanced technical systems, we provide high quality antibody generation services. Moreover, our high standards antibodies have allowed us to be actively involved in co-development with our partners and we are willing to expand co-development opportunities to other potential partners.
Under the collaboration with SAMSUNG MEDICAL CENTER, we have more than 300 patients-derived cancer stem cell libraries and an animal model system for evaluating internal pipeline development.
Additional information about PharmAbcine can be found on our website at http://www.pharmabcine.com